Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9Y5C1
UPID:
ANGL3_HUMAN
Alternative names:
Angiopoietin-5; Angiopoietin-like protein 3
Alternative UPACC:
Q9Y5C1; A0JLS0; B1ALJ0; B2RCW1
Background:
Angiopoietin-related protein 3, also known as Angiopoietin-5 or Angiopoietin-like protein 3, plays a crucial role in lipid and glucose metabolism, angiogenesis, and the regulation of hematopoietic stem cell activity. It influences plasma triglycerides levels, LDL-cholesterol, and HDL-cholesterol through various mechanisms, including the inhibition of lipoprotein lipase (LPL) activity and endothelial lipase.
Therapeutic significance:
Given its involvement in familial Hypobetalipoproteinemia, 2, a lipid metabolism disorder, understanding the role of Angiopoietin-related protein 3 could open doors to potential therapeutic strategies for managing lipid levels and preventing cardiovascular diseases.